Want to see NXTC full AI Analyst Report?
NXTC Stock Chart & Stats
$5.83
$0.70(16.51%)
At close: 4:00 PM EDT
$5.83
$0.70(16.51%)
Day’s Range― - ―
52-Week Range$1.55 - $15.74
Previous CloseN/A
Volume127.65K
Average Volume (3M)183.90K
Market Cap
$25.95M
Enterprise Value-$7.31
Total Cash (Recent Filing)$20.09M
Total Debt (Recent Filing)$4.29M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Oct 29, 2026EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.58
Shares Outstanding4,577,359
10 Day Avg. Volume88,606
30 Day Avg. Volume183,897
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$20.00Price Target Upside243.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-6.26
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageRelatively modest leverage gives the company more flexibility than highly indebted peers and limits the direct burden of interest and refinancing obligations. Although the balance sheet is weakening, low debt exposure remains a durable financial advantage as the business undergoes a strategic transition.
Merger Funding And PipelineThe transaction materially improves the combined company’s ability to fund clinical development, including multiple planned trials for AVR-001. Access to substantial committed capital can extend the development runway and support value creation from a defined therapeutic program over the next several quarters.
Lower Operating FootprintExiting the Beltsville facility removes ongoing rental commitments and consolidates the company’s physical footprint. This should lower the recurring cost base and preserve capital during the transition, making the post-restructuring organization more financially efficient than the prior operating setup.
Bears Say
No Commercial RevenueA continuing absence of revenue means the company has not yet established a commercial funding engine for its operations. With no product sales to offset research and development spending, future progress remains dependent on financing, partnerships, or successful clinical and regulatory execution.
Persistent Cash BurnSustained negative operating and free cash flow shows that the business is not self-funding and continues to consume capital. This dependence can constrain investment choices and leave the company reliant on external financing to maintain development activities over the medium term.
Severe Ownership DilutionThe merger substantially resets ownership economics for legacy shareholders, who are expected to retain only about 1–2% plus contingent value rights. This limits their participation in the combined company’s future upside and reflects a major change in corporate control and strategic direction.
NextCure News
NXTC FAQ
What was NextCure Inc’s price range in the past 12 months?
NextCure Inc lowest stock price was $1.55 and its highest was $15.74 in the past 12 months.
What is NextCure Inc’s market cap?
NextCure Inc’s market cap is $25.95M.
When is NextCure Inc’s upcoming earnings report date?
NextCure Inc’s upcoming earnings report date is Oct 29, 2026 which is in 40 days.
How were NextCure Inc’s earnings last quarter?
NextCure Inc released its earnings results on Aug 06, 2026. The company reported -$2.8 earnings per share for the quarter, missing the consensus estimate of -$1.95 by -$0.85.
Is NextCure Inc overvalued?
According to Wall Street analysts NextCure Inc’s price is currently Undervalued.
Does NextCure Inc pay dividends?
NextCure Inc does not currently pay dividends.
What is NextCure Inc’s EPS estimate?
NextCure Inc’s EPS estimate is -0.9.
How many shares outstanding does NextCure Inc have?
NextCure Inc has 4,577,359 shares outstanding.
What happened to NextCure Inc’s price movement after its last earnings report?
NextCure Inc reported an EPS of -$2.8 in its last earnings report, missing expectations of -$1.95. Following the earnings report the stock price went up 4.472%.
Which hedge fund is a major shareholder of NextCure Inc?
Currently, no hedge funds are holding shares in NXTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NextCure Inc
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
NXTC Stock 12 Month Forecast
Average Price Target
$20.00
▲(243.05% Upside)
Technical Analysis
GT Biopharma
―
Marker Therapeutics
―
Celularity
―
Werewolf Therapeutics
―
Senti Biosciences
―
Ownership Overview
22.53% Insiders
7.86% Mutual Funds
22.80% Other Institutional Investors
43.17% Public Companies and
Individual Investors